Wave of Antibody-Drug Conjugates Poised to Change Treatment Paradigms Across Multiple Cancers
The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard of care in pretreated patients across several different …